Rani治疗师错过了收入估计, 股票在一次大型内幕销售后下跌。 Rani Therapeutics missed earnings estimates, stock dropped after a major insider sale.

Rani治疗机构报告第二季度损失每股0.12美元,损失估计数为0.03美元。 Rani Therapeutics reported a second-quarter loss of $0.12 per share, missing estimates by $0.03. 股票在星期五下跌到2.02美元,交易量增加。 The stock dropped to $2.02 on Friday with elevated trading volume. 该公司通过其RaniPill平台开发口服生物学,市场上限为1.4518亿美元,分析家前景混杂,具有共识的“中价购买”评级和8.50美元目标。 The company, developing oral biologics via its RaniPill platform, has a market cap of $145.18 million and a mixed analyst outlook, with a consensus "moderate buy" rating and a $8.50 target. 机构投资者持有30.19%的股份,而内幕活动包括南锥体投资公司的重大销售和Mir A. Imran主任的重大购买。 Institutional investors hold 30.19% of shares, while insider activity included a major sale by South Cone Investments and a significant purchase by Director Mir A. Imran.